Clinical Trial Update: Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase II efficacy study of repotrectinib for ROS1-rearranged advanced non-small cell lung cancer in frail and/or elderly …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Repotrectinib (repotrectinib)

Snippet

Sponsor: Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer | Conditions: NSCLC Stage IV, NSCLC, Stage III | Phase 2 | Status: RECRUITING